Homepage - tenvie
Ten\vie: the tenacious (Ten\) pursuit to improve the lives (\vie) of patients and caregivers. Tenvie was purpose-built with a deep and diverse portfolio and a proven team of CNS drug developers with a collective track record of engineering and developing small molecule therapies.
News Archive - tenvie
We are thrilled to announce the official launch of Tenvie with a commitment to transform the treatment of neurological diseases. Follow us on our journey, covered by Global Newswire, STAT, Endpoints News, Fierce Biotech, and the San Francisco Business Times
Tenvie Therapeutics Launches with $200 Million to Deliver …
Jan 8, 2025 · Tenvie is developing a portfolio of wholly owned, highly brain-penetrant and peripherally restricted small molecules that address three key drivers of disease: resolving inflammation, rescuing ...
Tenvie Therapeutics Launches with $200 Million to Deliver …
Jan 8, 2025 · Tenvie is developing a portfolio of wholly owned, highly brain-penetrant and peripherally restricted small molecules that address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
Tenvie raises $200M for brain drug R&D; Sana spikes on
Jan 8, 2025 · A new San Francisco-area startup, Tenvie Therapeutics, launched on Wednesday with $200 million in funding. Tenvie is supported by Arch Venture Partners, F-Prime Capital and Mubadala Capital,...
Tenvie Therapeutics, a Denali spinout, raises $200M as neuro
Jan 8, 2025 · The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital, and...
Tenvie Therapeutics Launches with $200 Million to Deliver
Jan 9, 2025 · Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and ...
Tenvie takes off with $200M, assets and exec from Denali
Jan 8, 2025 · Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.
Tenvie Therapeutics Launches with $200M for Breakthrough …
Jan 9, 2025 · Tenvie Therapeutics launched with $200 million in funding to develop small molecule treatments for neurological diseases. The company acquired assets from Denali Therapeutics and assembled a leadership team with expertise in …
Tenvie launches with $200m to combat age-related diseases
Jan 10, 2025 · Backed with a whopping $200 million in funding, US biotech Tenvie Therapeutics has launched to advance new treatments for neurological, cardiometabolic and ophthalmic diseases.